Biomea Fusion's experimental drug showed sustained blood sugar control in patients with type 2 diabetes and may benefit those not responding to GLP-1 therapies like Novo Nordisk's Ozempic, it said on ...
Biomea Fusion (NASDAQ:BMEA) shares rose after reporting positive results from its mid-stage study testing icovamenib in individuals with type 2 diabetes over a 52-week period. The stock closed up 24% ...
The Fezawio Octa-Core 2-in-1 Laptop and Tablet is on sale as an early Prime Day deal for just $80. There's no telling how quickly this amazing machine might sell out, so why not click buy now, while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback